Drugs / verenafusp alfa
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06475404 | Apr → Sep 2023 | mucopolysaccharidosis type 2 | AO GENERIUM | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | verenafusp alfa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06475404 ↗ |
| Action | Restore | “GNR-055 (verenafusp alfa) is intended for enzyme replacement therapy (ERT)” NCT06475404 ↗ |
| Modality | Protein / enzyme biologic | “GNR 055 (verenafusp alfa) is a modified enzyme I2S capable of penetrating the blood-brain barrier” NCT06475404 ↗ |
| Route | Intravenous | “Single intravenous administration of 6 mg/kg of verenafusp alfa” NCT06475404 ↗ |